PET/CT plays a critical role in evaluating patients with relapsed/refractory multiple myeloma (RRMM) undergoing B‐cell maturation antigen (BCMA)‐directed CAR T cell therapy. The gene discussed is TNFRSF17; the disease is AL amyloidosis.